Northern Trust Corp raised its stake in shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 480,584 shares of the biotechnology company’s stock after purchasing an additional 8,943 shares during the period. Northern Trust Corp owned 1.00% of Aeglea BioTherapeutics worth $3,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently modified their holdings of the company. Citigroup Inc. lifted its holdings in Aeglea BioTherapeutics by 107.8% during the 4th quarter. Citigroup Inc. now owns 10,076 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 5,227 shares in the last quarter. Personal CFO Solutions LLC purchased a new stake in Aeglea BioTherapeutics in the fourth quarter valued at approximately $90,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Aeglea BioTherapeutics in the third quarter worth $89,000. JPMorgan Chase & Co. grew its position in Aeglea BioTherapeutics by 10.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,654 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 1,531 shares during the period. Finally, ProShare Advisors LLC raised its position in Aeglea BioTherapeutics by 41.0% during the fourth quarter. ProShare Advisors LLC now owns 17,400 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 5,063 shares in the last quarter. Institutional investors own 80.87% of the company’s stock.
NASDAQ:AGLE opened at $7.55 on Thursday. Aeglea BioTherapeutics, Inc. has a 12-month low of $4.91 and a 12-month high of $11.38. The firm has a market cap of $362.52 million, a PE ratio of -3.95 and a beta of 1.66. The stock has a fifty day moving average price of $7.73 and a 200 day moving average price of $7.95.
Separately, Zacks Investment Research upgraded shares of Aeglea BioTherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $11.69.
Aeglea BioTherapeutics Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.
Featured Story: Yield Curve
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.